DPP4 and type 2 diabetes mellitus: Sitagliptin was the first selective DPP-4 inhibitor approved by the US Food and Drug Administration (FDA) in 2006 for T2DM treatment followed by the development of a number of other selective DPP-4 inhibitors [13,14].